演題抄録

International Symposium

開催概要
開催回
第51回・2013年・京都
 

Immunotherapy for cervical neoplasia through HPV E7-specific mucosal immunity

演題番号 : IS2-3

[筆頭演者]
Kei Kawana:1 

1:Dept. of Obstetrics and Gynecology, Graduate School of Med., Univ. of Tokyo, Japan

 

Among sexually transmitted infection Human Papillomavirus (HPV) is detected in almost every female cervix and one per 200-300 women develop cervical cancer. Prophylactic HPV vaccines have been introduced worldwide and its efficacy has been proved. Therapeutic HPV vaccine has also attracted attention as a cancer immunotherapy agent.However, therapeutic HPV vaccine to eradicate HPV infection sites on mucosal epithelium lining the uterine cervix has not been developed. The reason is that the cell-mediated immunity against HPV is not induced in the cervical area by vaccination systemically.In this study, firstly, we found homing of Integrin B7 positive intestinal mucosal lymphocyte on the cervical mucosa. Next, in order to induce anti-HPV cellular immunity directly to intestinal mucosa, HPV E7-expressing Lactobacillus casei (LacE7) was generated. We confirmed that anti E7 IFNgamma-producing cells are induced in mice by oral administration of the vaccine and conducted phase I and phase IIa clinical trials on cervical precancer lesions (CIN3). Some patients with CIN3 showed regression after oral administration of LacE7 1g/day. We then confirmed induction of anti-E7 IFNgamma-producing cells in the cervix lymphocytes obtained from these patients. Furthermore, along with administration of Chinese herbal medicine (Hochuekkitou) as adjuvant, we have been conducting basic research to make improvements by optimizing component configuration of Hochuekkitou, HPVE7, and alphaGalCer. In this presentation, I will introduce some findings on mucosal immunity in the female genital organs and research on immunotherapy targeting HPV molecule through mucosal immunity.

前へ戻る